TY - JOUR
T1 - Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System
AU - Britt, Rachel S.
AU - Evoy, Kirk E.
AU - Lee, Grace C.
AU - Reveles, Kelly R.
AU - Sorensen, Kimberly M.
AU - Jones, Xavier
AU - Bollinger, Mary
AU - Frei, Christopher R.
N1 - Funding Information:
The contents of this article do not necessarily represent the views of the US Department of Veterans Affairs or the US Government. Furthermore, Dr. Reveles is supported by the NIH/National Institute on Aging San Antonio Claude D. Pepper Older Americans Independence Center (1P30AG044271-01A1) Career Development (KL2) Program. Finally, Dr. Frei is supported by the National Center for Advancing Translational Sciences, NIH, through Grant UL1 TR001120. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was supported by Allergan Pharmaceuticals (formerly Forest Pharmaceuticals) [TEF-IT-41 to CRF’s institution].
Publisher Copyright:
© 2017, Springer International Publishing AG.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Background: Ceftaroline fosamil is US Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, but it is not known how ceftaroline is being used in real-world settings or how adverse effects (AEs) and mortality compare to clinical trials. Objective: This study describes ceftaroline use, AEs, and mortality in US Veterans Health Administration (VHA) hospital patients. Methods: This phase IV, population-based, epidemiologic study analyzed patients ≥18 years old who received one or more ceftaroline doses within 14 days of admission to 69 VHA hospitals in 41 US states/territories from 1 October 2010 to 30 September 2014. VHA repository data were linked using unique patient identifiers. Diagnoses and AEs were determined using ICD9-CM and CSS codes. Demographics, AEs within 30 days of therapy initiation, and all-cause in-hospital mortality were summarized using descriptive statistics. Results: 764 Patients met study criteria. Patients were 97% male and 56% White, with a median age of 61 years and a Charlson score of 6. Diagnoses included skin (40%), sepsis (30%), osteomyelitis (25%), diabetic foot (22%), pneumonia (16%), bacteremia (11%), endocarditis (6%), meningitis (2%), and device (2%) infections. Ceftaroline was used first-line (37%), second-line (56%), and third-line or greater (7%). Patients received ceftaroline a median of 3 days after hospital admission. All-cause in-hospital mortality rates were: overall (5%), skin (2%), sepsis (9%), osteomyelitis (3%), diabetic foot (1%), pneumonia (13%), bacteremia (6%), endocarditis (11%), meningitis (6%), and device (13%). Eosinophilia, leukopenia, leukocytosis, fibromyalgia, myalgia and myositis, and polymyalgia rates were <1% each. Conclusions: Ceftaroline is used in VHA hospitals for various diagnoses. Mortality was low and comparable with rates from clinical trials. Additional studies comparing ceftaroline to other drugs used in similar situations are needed.
AB - Background: Ceftaroline fosamil is US Food and Drug Administration-approved for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, but it is not known how ceftaroline is being used in real-world settings or how adverse effects (AEs) and mortality compare to clinical trials. Objective: This study describes ceftaroline use, AEs, and mortality in US Veterans Health Administration (VHA) hospital patients. Methods: This phase IV, population-based, epidemiologic study analyzed patients ≥18 years old who received one or more ceftaroline doses within 14 days of admission to 69 VHA hospitals in 41 US states/territories from 1 October 2010 to 30 September 2014. VHA repository data were linked using unique patient identifiers. Diagnoses and AEs were determined using ICD9-CM and CSS codes. Demographics, AEs within 30 days of therapy initiation, and all-cause in-hospital mortality were summarized using descriptive statistics. Results: 764 Patients met study criteria. Patients were 97% male and 56% White, with a median age of 61 years and a Charlson score of 6. Diagnoses included skin (40%), sepsis (30%), osteomyelitis (25%), diabetic foot (22%), pneumonia (16%), bacteremia (11%), endocarditis (6%), meningitis (2%), and device (2%) infections. Ceftaroline was used first-line (37%), second-line (56%), and third-line or greater (7%). Patients received ceftaroline a median of 3 days after hospital admission. All-cause in-hospital mortality rates were: overall (5%), skin (2%), sepsis (9%), osteomyelitis (3%), diabetic foot (1%), pneumonia (13%), bacteremia (6%), endocarditis (11%), meningitis (6%), and device (13%). Eosinophilia, leukopenia, leukocytosis, fibromyalgia, myalgia and myositis, and polymyalgia rates were <1% each. Conclusions: Ceftaroline is used in VHA hospitals for various diagnoses. Mortality was low and comparable with rates from clinical trials. Additional studies comparing ceftaroline to other drugs used in similar situations are needed.
UR - http://www.scopus.com/inward/record.url?scp=85021712151&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021712151&partnerID=8YFLogxK
U2 - 10.1007/s40265-017-0785-2
DO - 10.1007/s40265-017-0785-2
M3 - Article
C2 - 28664412
AN - SCOPUS:85021712151
SN - 0012-6667
VL - 77
SP - 1345
EP - 1351
JO - Drugs
JF - Drugs
IS - 12
ER -